| Literature DB >> 35777055 |
Yan Gao1,2, Lina Du1,2, Qian Li1,2, Qi Li1,2, Lin Zhu2, Meiyan Yang3, Xiu Wang4, Bonian Zhao1, Shan Ma5.
Abstract
BACKGROUND: Transdermal delivery is very important in pharmaceutics. However, the barrier function of the stratum corneum hinders drugs absorption. How to improve transdermal delivery efficiency is a hot topic. The key advantages of physical technologies are their wide application for the delivery of previously nonappropriate transdermal drugs, such as proteins, peptides, and hydrophilic drugs. Based on the improved permeation of drugs delivered via multiple physical techniques, many more diseases may be treated, and transdermal vaccinations become possible. However, their wider application depends on the related convenient and portable devices. Combined products comprising medicine and devices represent future commercial directions of artificial intelligence and 3D printing.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35777055 PMCID: PMC9239599 DOI: 10.1097/MD.0000000000029314
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Drugs approved by FDA for transdermal administration.
| Drugs | Company | Indication | Approval year |
|---|---|---|---|
| Rivastigmine | Novartis | Dementia | 2007 |
| Rotigotine | UCB, Inc. | Parkinson disease | 2007 |
| Granisetron | Prostrakan, Inc. | Chemotherapy-induced nausea and vomiting | 2008 |
| Oxybutynin | Watson | Urinary incontinence | 2009 |
| Chloride | Allergan | Overactive bladder | 2009 |
| Buprenorphine | Purdue Pharma L. P | Pain and opioid dependence | 2010 |
| Scopolamine | Glaxosmithkline CON | Motion thickness | 1979 |
| Nitroglycerin | Hospira | Angina pectori | 1981 |
| Clonidine | Boehringer Ingelheim | Hype tension | 1984 |
| Estradio | Novartis | Menopausal symptoms | 1986 |
| Fentanyl | JANSSEN PHARMS | Chronic pain | 1990 |
| Nicotine | Sanofi-Aventis US | Smoking cessation | 1991 |
| Testosterone | Alza Pharmaceuticals | Testosterone deficiency | 1993 |
| Estradiol/norethisterone | Parke Davis | Menopausal symptoms | 1996 |
| Ethinylestradiol/norelgestromin | JANSSEN PHARMS | Contraception | 2001 |
| Estradiol/levonorgestrel | BAYER HLTHCARE | Menopausal symptoms | 2003 |
| Lidocaine with tetracaine | Local dermal analgesia | 2004 | |
| Methylphenidate | NOVEN PHARMS INC. | Hyperactivity disorder | 2006 |
| Selegiline | Somerset | Depressive disorder | 2006 |
| Diclofenac epolamine | Inst. Biochem. | Acute pain | 2007 |
| Capsaicin | Neuropathy pain | 2009 | |
| Influenza-virus vaccine | Influenza virus | 2011 |
FDA = Food and Drug Administration.
Companies developing and commercializing skin permeability technologies.
| Technologies | Company | Product | Mechanism |
|---|---|---|---|
| Low-frequency sonophoresis/Sensing | Echo Therapeutics, Inc. | Symphony Continuous | Glucose monitoring by interstitial fluid after skin |
| Glucose Monitor | Permeability | ||
| Microneedles | Becton Dickinson/Sanofi Pasteur | Intanza | Prefillable injection system utilizing the microneedle for delivery of vaccine against seasonal influenza |
| Corium International, Inc. | MicroCor | Dissolvable microneedle device | |
| NanoPassTechnologies, Ltd. | MicronJet | Hollow microneedle device | |
| Seventh Sense Biosystems, Inc | TAP 20C | Microneedle penetration of the skin followed by application of vacuum for blood extraction | |
| TheraJect | TheraJect Patch | Dissolvable microneedle device | |
| Valeritas, Inc. | Micro-Trans | Microneedle device | |
| Vaxxas, Inc. | The Nanopatch | Vaccine-coated microneedle device | |
| ZosanoPharma | ZP Patch | Drug-coated microneedle patch | |
| Electrical techniques | Ichor Medical Systems | TriGrid Delivery System | Electroporation platform for vaccination |
| Inovio Pharmaceuticals, Inc. | Cellectr | Electroporation platform for vaccination | |
| NuPathe, Inc. | Zecuit | Iontophoresis-facilitated delivery of sumatriptan for acute treatment of migraines | |
| OncoSec Medical, Inc. | OncoSec Medical System | Electroporation platform for vaccination | |
| NB Therapeutics | Iontophoresis Platform | Iontophoresis-facilitated delivery of terbinafine HCl for the treatment of toenail fungus |
Figure 1.Schematic illustration of hollow and solid microneedles.
Figure 2.Overview of the different mechanisms of laser-facilitated drug delivery. SC = stratum corneum.
Figure 3.Iontophoresis for transdermal permeation. (A) The principle of iontophoresis using an Ag/AgCl electrode system. (B), (C) Commercial formulations using iontophoresis. A− = anionic drugs, Cl− = chloride ions in the drug reservoir, D+ = cationic drugs, FDA = Food and Drug Administration, Na+ = sodium ions in the drug reservoir.
Figure 4.Sonophoresis for transdermal permeation. (A) Low-frequency ultrasound treatment in a clinical setting with the SonoPrep® device (Echo Therapeutics, Franklin, MA). (B) Ultrasound transducer, 3.5-cm diameter. (C) Mechanistic overview of sonophoresis-facilitated drug delivery
Figure 5.Electroporation for transdermal permeation. (A) The components of an electroporation device. (B) Electroporation pin electrodes arranged in a honeycomb configuration. (C) Mechanistic overview of electroporation facilitated drug delivery.
Figure 6.Schematic representation of a magnetic nanoparticle-based drug delivery system. The steps for magnetic NP-based drug delivery are: Coupling the drug to the MNP; applying an external magnetic field to attract the MNP to the desired location, such as a tumor; and the release of the drugs from the NP under the influence of an external alternating magnetic field once it reaches the target. MNP = magnetic nanoparticle, NP = nanoparticle.
Figure 7.3D printing in transdermal delivery. CAD = computer-aided design, CAM = computer aided manufacturing, MN = microneedle, PC = personal computer.
Figure 8.Different physical techniques to improve transdermal delivery.
Comparison of different physical technologies used for drug delivery.
| Physical energy | Electric field | Magnetic field | Temperature | Ultrasound | Light |
|---|---|---|---|---|---|
| Poration | Electroporation | MNP | Thermoporation | Sonoporation | Optoporation |
| Limitations | Narrow range of clinically safe electric field parameters (refer to current standards for safety levels) | Limited drug carrying capacity of magnetic field due to their biodistribution | Low penetration depth (since only applied topically so far) | Sonoporation devices have poor calibration in terms of the amount of ultrasound energy emitted | Limited time duration between optoporation and drug delivery |
| Narrow range of magnetic field | |||||
| Disadvantages | Irreversible electroporation, cell death with high fields | Aggregation of MNP can cause embolization | Excess heat can induce thermohemolysis | Shear forces may induce rupture of cells | Excessive inflammation, postinflammatory, and hyperpigmentation |
| Electromechanical coupling effect | Cytotoxicity increases with the increased concentrations of MNP | Relies on electric field to heat up the filaments; therefore, the disadvantages of electric field applies | Temperature increases as a function of frequency and eventually disrupts cells | Laser usage and ultrastructural changes in epidermis | |
| Advantages | Inexpensive and simple to perform | Noninvasive nature of the magnetic field | Noninvasive nature of low heat compared to EP | Less invasive compared to EP | Remote operation with less cellular damage |
| Drugs are easy to overcome the cell membrane barrier | Field modulated externally without electrode contacts unlike EP | Selective irreparable cellular damage | Instant impermeabilization after ultrasound exposure | Enhanced optofection efficiency compared with regular gene delivery | |
| High efficiency of drugs delivery compared with that without the magnetic field | Deep penetration; key nanosurgical tool to the microscopist |
EP = electroporation, MNP = magnetoporation.